Marshall Wace, LLP Belite Bio, Inc Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Belite Bio, Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 8,486 shares of BLTE stock, worth $474,706. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,486Holding current value
$474,706% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding BLTE
# of Institutions
16Shares Held
79.1KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA20.1KShares$1.12 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC13.5KShares$752,4480.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$374,7980.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il6.46KShares$361,3720.0% of portfolio
-
Jpmorgan Chase & CO New York, NY6.36KShares$355,5540.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.39B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...